Healthcare provider profile · identity verified

Barney Rubenstein, MD

Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · GREENWICH, NY · NPI 1356339469

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Barney Rubenstein, MD received $22.82 in general payments during 2025 across 1 reported records.

PFIZER INC. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Eliquis by this doctor in 2024.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$22.82

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
PFIZER INC.	Unresolved — no canonical attribution shown	$22.82	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$22.82	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
ELIQUIS Normalized: eliquis	Drug	PFIZER INC.	$22.82	1	2025
Source payment records 2025-11-05 · PFIZER INC. · $22.82 · Open Payments source
NURTEC ODT Normalized: nurtec odt	Drug	PFIZER INC.	$22.82	1	2025
Source payment records 2025-11-05 · PFIZER INC. · $22.82 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
ELIQUIS eliquis	2025	Eliquis	2024	252	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
PFIZER INC. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063	Eliquis · 2024 Exact normalized brand match · 1 Part D row	252	49
PFIZER INC. Exact reporting entity; no affiliate inference	2025	PAXLOVID open payments reported associated product	CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432	Paxlovid · 2024 Exact normalized brand match · 1 Part D row	16	15

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	928	220
Lisinopril	Lisinopril	713	164
Omeprazole	Omeprazole	631	170
Levothyroxine Sodium	Levothyroxine Sodium	532	130
Amlodipine Besylate	Amlodipine Besylate	512	128
Rosuvastatin Calcium	Rosuvastatin Calcium	336	86
Duloxetine Hcl	Duloxetine Hcl	314	61
Gabapentin	Gabapentin	304	67
Losartan Potassium	Losartan Potassium	290	75
Eliquis	Apixaban	252	49
Albuterol Sulfate Hfa	Albuterol Sulfate	240	67
Trazodone Hcl	Trazodone Hcl	222	50
Furosemide	Furosemide	213	49
Sertraline Hcl	Sertraline Hcl	199	51
Metoprolol Succinate	Metoprolol Succinate	193	56
Hydrochlorothiazide	Hydrochlorothiazide	187	57
Tamsulosin Hcl	Tamsulosin Hcl	185	56
Metformin Hcl	Metformin Hcl	179	40
Metoprolol Tartrate	Metoprolol Tartrate	162	39
Fluticasone Propionate	Fluticasone Propionate	155	40
Metformin Hcl Er	Metformin Hcl	155	35
Simvastatin	Simvastatin	144	43
Pravastatin Sodium	Pravastatin Sodium	143	38
Escitalopram Oxalate	Escitalopram Oxalate	140	33
Famotidine	Famotidine	134	31
Mirtazapine	Mirtazapine	133	27
Allopurinol	Allopurinol	129	28
Farxiga	Dapagliflozin Propanediol	127	23
Clopidogrel	Clopidogrel Bisulfate	119	26
Potassium Chloride	Potassium Chloride	115	27
Alendronate Sodium	Alendronate Sodium	112	30
Prednisone	Prednisone	109	68
Pantoprazole Sodium	Pantoprazole Sodium	103	27
Montelukast Sodium	Montelukast Sodium	102	24
Tramadol Hcl	Tramadol Hcl	97	27
Glimepiride	Glimepiride	93	26
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	90	26
Ozempic	Semaglutide	86	21
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	84	20
Clonazepam	Clonazepam	82	16
Oxycodone Hcl	Oxycodone Hcl	80	19
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	74	21
Glipizide Er	Glipizide	73	18
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	72	17
Atenolol	Atenolol	70	16
Incruse Ellipta	Umeclidinium Bromide	67	16
Isosorbide Mononitrate Er	Isosorbide Mononitrate	67	16
Ezetimibe	Ezetimibe	66	18
Finasteride	Finasteride	64	17
Mometasone Furoate	Mometasone Furoate	60	23
Spironolactone	Spironolactone	60	14
Doxycycline Hyclate	Doxycycline Hyclate	59	43
Citalopram Hbr	Citalopram Hydrobromide	58	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	54	suppressed
Synthroid	Levothyroxine Sodium	52	14
Chlorthalidone	Chlorthalidone	49	12
Clonidine Hcl	Clonidine Hcl	48	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	48	13
Fluoxetine Hcl	Fluoxetine Hcl	47	suppressed
Alprazolam	Alprazolam	45	21
Januvia	Sitagliptin Phosphate	45	suppressed
Breo Ellipta	Fluticasone/Vilanterol	44	11
Carvedilol	Carvedilol	44	11
Trulicity	Dulaglutide	44	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	44	11
Propranolol Hcl	Propranolol Hcl	42	12
Benazepril Hcl	Benazepril Hcl	40	11
Lorazepam	Lorazepam	40	11
Celecoxib	Celecoxib	38	suppressed
Donepezil Hcl	Donepezil Hcl	38	12
Ropinirole Hcl	Ropinirole Hcl	37	suppressed
Valsartan	Valsartan	35	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	34	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	34	suppressed
Ketoconazole	Ketoconazole	34	15
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	34	27
Topiramate	Topiramate	33	suppressed
Xarelto	Rivaroxaban	33	suppressed
Bupropion Xl	Bupropion Hcl	31	suppressed
Lansoprazole	Lansoprazole	31	suppressed
Jardiance	Empagliflozin	30	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	30	suppressed
Buspirone Hcl	Buspirone Hcl	28	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	28	11
Venlafaxine Hcl Er	Venlafaxine Hcl	28	suppressed
Azelastine Hcl	Azelastine Hcl	27	12
Tradjenta	Linagliptin	27	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	26	12
Pregabalin	Pregabalin	26	suppressed
Propranolol Hcl Er	Propranolol Hcl	26	suppressed
Glipizide	Glipizide	25	suppressed
Warfarin Sodium	Warfarin Sodium	24	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	23	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	23	suppressed
Ramipril	Ramipril	23	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	22	suppressed
Symbicort	Budesonide/Formoterol Fumarate	22	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Paroxetine Hcl	Paroxetine Hcl	21	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Ondansetron Hcl	Ondansetron Hcl	20	suppressed
Testosterone Cypionate	Testosterone Cypionate	20	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	19	suppressed
Amoxicillin	Amoxicillin	19	16
Carbamazepine	Carbamazepine	19	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	19	suppressed
Nystatin	Nystatin	19	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	19	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Ibuprofen	Ibuprofen	18	suppressed
Verapamil Er	Verapamil Hcl	18	suppressed
Meclizine Hcl	Meclizine Hcl	17	suppressed
Naltrexone Hcl	Naltrexone Hcl	17	suppressed
Bupropion Hcl Sr	Bupropion Hcl	16	suppressed
Hydrocortisone	Hydrocortisone	16	suppressed
Invokana	Canagliflozin	16	suppressed
Liothyronine Sodium	Liothyronine Sodium	16	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	16	suppressed
Myrbetriq	Mirabegron	16	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	16	15
Temazepam	Temazepam	16	suppressed
Torsemide	Torsemide	16	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	13
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	15	suppressed
Lovastatin	Lovastatin	15	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	15	suppressed
Terazosin Hcl	Terazosin Hcl	15	suppressed
Dexamethasone	Dexamethasone	14	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	14	suppressed
Meloxicam	Meloxicam	14	suppressed
Bydureon Bcise	Exenatide Microspheres	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	12	suppressed
Cephalexin	Cephalexin	12	suppressed
Dantrolene Sodium	Dantrolene Sodium	12	suppressed
Metolazone	Metolazone	12	suppressed
Nifedipine Er	Nifedipine	12	suppressed
Roflumilast	Roflumilast	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Tizanidine Hcl	Tizanidine Hcl	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Bupropion Hcl	Bupropion Hcl	11	suppressed
Diazepam	Diazepam	11	suppressed
Divalproex Sodium	Divalproex Sodium	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Fluconazole	Fluconazole	11	11
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Ibu	Ibuprofen	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Morphine Sulfate Er	Morphine Sulfate	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Oxymorphone Hcl Er	Oxymorphone Hcl	11	suppressed
Rexulti	Brexpiprazole	11	suppressed
Spiriva Handihaler	Tiotropium Bromide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$22.82 · 1 records	PFIZER INC.	ELIQUIS, NURTEC ODT	2	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Eliquis play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error